Previous 10 | Next 10 |
2024-04-22 16:25:25 ET More on Abeona Therapeutics Abeona issues update on FDA market application for pz-cel Seeking Alpha’s Quant Rating on Abeona Therapeutics Historical earnings data for Abeona Therapeutics Financial information for Abeona Therapeut...
Receives FDA Complete Response Letter (CRL) based on need for additional CMC information CRL did not identify deficiencies related to clinical efficacy or clinical safety data in BLA, and no new clinical studies requested by FDA to support approval Anticipates completing and sub...
2024-04-16 21:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-07 00:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-19 06:53:51 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abeona Therapeutics (NASDAQ: ABEO ) just reported results for the fourth quarter of 2023. Abeona Therapeutics reported earnings per share of -64 cents. This was below the ...
2024-03-18 10:00:18 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Johnson & Johnson, Boston...
2024-03-18 07:41:37 ET More on Abeona Therapeutics Abeona issues update on FDA market application for pz-cel Abeona Therapeutics announces $50M credit facility Seeking Alpha’s Quant Rating on Abeona Therapeutics Historical earnings data for Abeona Ther...
CLEVELAND, March 18, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2023 and provided an update on progress toward achieving key corporate objectives. Abeona also announced today that the U.S. Food and Drug Administrati...
2024-02-07 10:31:12 ET More on Abeona Therapeutics Abeona issues update on FDA market application for pz-cel Abeona Therapeutics announces $50M credit facility Seeking Alpha’s Quant Rating on Abeona Therapeutics Historical earnings data for Abeona Ther...
2024-02-01 11:48:30 ET More on Abeona Therapeutics Abeona Therapeutics Inc. (ABEO) Q3 2023 Earnings Call Transcript Abeona Therapeutics announces $50M credit facility Abeona shares jump after FDA priority review for epidermolysis bullosa drug Seeking Alpha...
News, Short Squeeze, Breakout and More Instantly...
Abeona Therapeutics Inc. Company Name:
ABEO Stock Symbol:
NASDAQ Market:
Abeona Therapeutics Inc. Website:
BLA resubmission anticipated in second half of 2024 Closed $75 million underwritten offering in May, extending expected cash runway into 2026 CLEVELAND, May 15, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter ...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
CLEVELAND, May 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) (“Abeona” or the “Company”) today announced the pricing of an underwritten offering of 12,285,056 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchas...